Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
1 mg
5 mg
10 mg
1 mM
1.9357 mL
9.6787 mL
19.3573 mL
5 mM
0.3871 mL
1.9357 mL
3.8715 mL
10 mM
0.1936 mL
0.9679 mL
1.9357 mL
50 mM
0.0387 mL
0.1936 mL
0.3871 mL
Description
BAF312 (Siponimod) is a next-generation S1P receptor agonist, selective for and receptors with of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.
BAF312 (Siponimod) is a potent and selective S1P receptor agonist, with EC50 of 0.39 nM and 0.98 nM for S1P and S1Preceptors, exhibits >1000-fold selectivity over S1P, S1P and S1P receptors. BAF312 (1 h at 1 μM) promotes prominent internalization of S1P1 receptors by 91%.
In vivo
BAF312 effectively suppresses encephalomyelitis (EAE) in rats by internalizing S1P receptors, rendering them insensitive to the egress signal from lymph nodes. BAF312 significantly reduces clinical scores when dosed prophylactically or therapeutically in mice at 0.3 mg/kg.
